This post was originally published on this site
Sanofi conducts much of its business in the United States and since it reports results in terms of the euro currency, it would benefit from the strength of the U.S. dollar against the euro.
Sanofi said its preliminary estimate of currency movements were for a boost of between 4.5%-5.5% on Q4 sales and a positive impact of between 6%-7% on its fourth quarter core earnings per share.
